In Silico Molecular Docking of Indigofera tinctoria Phytocompounds to Target EGFR/ERK and FGFR/FGF Pathway Proteins Involved in Prostate Cancer

Year : 2023 | Volume : 01 | Issue : 01 | Page : 34 56
    By

    Nidhi Premanand Honavar,

  1. Student, Department of Biotechnology,Bangalore Indian Academy Degree College Autonomous, Hennur, Karnataka, India

Abstract

Objective: Prostate cancer being the second major cause of cancer-related deaths in males, affects the small walnut-shaped gland below the bladder called the prostate gland. The epidermal growth factor protein (EGFR), cascade protein (ERK), and fibroblast growth factor proteins (FGFR and FGF) are involved in the different signaling pathways that lead to the formation of different products, that are responsible for the progression of cancer and thus can be considered as the therapeutic targets. Indigofera tinctoria, a medicinal plant with proven anti-cancerous properties, was chosen for this study to investigate its different compound’s therapeutic effects against the target proteins, which are responsible for prostate cancer. Methods: In this study, 20 different compounds were selected from the Indigofera tinctoria plant as ligands to check for their binding affinity against the target proteins (EGFR, ERK, FGFR, and FGF). The docking of the ligands with the target proteins was done by using the PyRx Virtual tool. The computational investigation of all the ligands and the target proteins, such as their molecular structure, phytochemistry, therapeutic actions, and other data was carried out. The protein structure validation and the pharmacological evaluation of the ligands were done using the BIOVIA Discovery Studio, pdb sum generate, and ADMET lab 2.0, respectively. Result: The results of this study showed that the compounds, Pseudosemiglabrin, [(12S,15R,16R)-14,14-dimethyl-6-oxo-4-phenyl-3,11,13-trioxatetracyclo [8.6.0.02,7.012,16] hexadeca-1(10),2(7),4,8-tetraen-15-yl] acetate, Deguelin, Sumatrol and Rotenone showed good binding affinity with the target proteins and can be considered as a potential drug for the prostate cancer. Conclusion: The compounds selected were found to be active against the target proteins for prostate cancer and thus can be utilized for cancer suppression. Further in vitro studies need to be done to support this study.

Keywords: Prostate cancer, molecular docking, Indigofera tinctoria, epidermal growth factor receptors, fibroblast growth factor receptors, extracellular regulated kinase, ADMET lab 2.0

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Nidhi Premanand Honavar. In Silico Molecular Docking of Indigofera tinctoria Phytocompounds to Target EGFR/ERK and FGFR/FGF Pathway Proteins Involved in Prostate Cancer. International Journal of Molecular Biotechnological Research. 2023; 01(01):34-56.
How to cite this URL:
Nidhi Premanand Honavar. In Silico Molecular Docking of Indigofera tinctoria Phytocompounds to Target EGFR/ERK and FGFR/FGF Pathway Proteins Involved in Prostate Cancer. International Journal of Molecular Biotechnological Research. 2023; 01(01):34-56. Available from: https://journals.stmjournals.com/ijmbr/article=2023/view=104221


Browse Figures

References

1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89. doi: 10.14740/wjon1191.
2. Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020;5(1):181. doi: 10.1038/s41392–020–00222–7.
3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16. doi: 10.1016/j.gene.2005.10.018.
4. Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13(11):2748. doi: 10.3390/cancers13112748.
5. Giacomini A, Grillo E, Rezzola S, Ribatti D, Rusnati M, Ronca R et al. The FGF/FGFR system in the physiopathology of the prostate gland. Physiol Rev. 2021;101(2):569–610. doi: 10.1152/physrev.00005.2020.
6. Chen KL, Chang WSW, Cheung CHA, Lin CC, Huang CC, Yang YN et al. Targeting cathepsin S induces tumor cell autophagy via the EGFR–ERK signaling pathway. Cancer Lett. 2012;317(1):89–98. doi: 10.1016/j.canlet.2011.11.015.
7. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563–9. doi: 10.1016/j.tig.2004.08.007.
8. Lu Y, Liu B, Liu Y, Yu X, Cheng G. Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity. Oncol Lett. 2020;20(2):993–1000. doi: 10.3892/ol.2020.11684.
9. Motamarri NS, Karthikeyan M, Rajasekar S, Gopal V. Indigofera tinctoria Linn-a phytopharmacological review. Int J Res Pharm Biomed Sci. 2012;3(1):164–9.
10. Thamilselvan V, Menon M, Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway. Int J Cancer. 2011;129(12):2916–27. doi: 10.1002/ijc.25949.
11. Ahmed Hassan LE, Khadeer Ahamed MB, Abdul Majid AS, Iqbal MA, Al Suede FS, Haque RA et al. Crystal structure elucidation and anticancer studies of (-)-pseudosemiglabrin: a flavanone isolated from the aerial parts of Tephrosia apollinea. PLOS ONE. 2014;9(6):e90806. doi: 10.1371/journal.pone.0090806.
12. Gerhäuser C, Mar W, Lee SK, Suh N, Luo Y, Kosmeder J et al. Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat Med. 1995;1(3):260–6. doi: 10.1038/nm0395–260.
13. Wei YF, Su J, Deng ZL, Zhu C, Yuan L, Lu ZJ, Zhu QY. [Indirubin inhibits the proliferation of prostate cancer PC-3 cells]. Zhonghua Nan Ke Xue. 2015 Sep;21(9):788–91. Chinese.
14. Choi S, Choi Y, Dat NT, Hwangbo C, Lee JJ, Lee JH. Tephrosin induces internalization and degradation of EGFR and ErbB2 in HT-29 human colon cancer cells. Cancer Lett. 2010;293(1):23–30. doi: 10.1016/j.canlet.2009.12.012.
15. Da J, Xu M, Wang Y, Li W, Lu M, Wang Z. Kaempferol promotes apoptosis while inhibiting cell proliferation via androgen-dependent pathway and suppressing vasculogenic mimicry and invasion in prostate cancer. Anal Cell Pathol (Amst). 2019;2019:1907698. doi: 10.1155/2019/1907698.
16. Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Syst Biol. 2009;3(1):100. doi: 10.1186/1752–0509–3–100.
17. Renukadevi KP, Sultana SS. Determination of antibacterial, antioxidant and cytotoxicity effect of Indigofera tinctoria on lung cancer cell line NCI-h69. Int J Pharmacol. 2011;7(3):356–62. doi: 10.3923/ijp.2011.356.362.
18. Srinivasan N. Medicinal plants for cancer treatment: a review approach. Int J Biol, (Research). 2018;3(4):57–61.
19. Szymczyk J, Sluzalska KD, Materla I, Opalinski L, Otlewski J, Zakrzewska M. FGF/FGFR-dependent molecular mechanisms underlying anti-cancer drug resistance. Cancers. 2021;13(22):5796. doi: 10.3390/cancers13225796.
20. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5-W14. doi: 10.1093/nar/gkab255.
21. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118(10):793–803. doi: 10.7326/0003–4819–118–10–199305150–00007.
22. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6):3–12. doi: 10.1016/j.urology.2003.10.013.
23. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–42. doi: 10.1001/jama.2017.7248.
24. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. doi: 10.1101/cshperspect.a030361.

Regular Issue Subscription Original Research
Volume 01
Issue 01
Received 02/03/2023
Accepted 02/04/2023
Published 18/04/2023
Publication Time 47 Days
937

Login


My IP

PlumX Metrics